Hepatitis

  • Most Topular Stories

  • Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (

    HCV Support
    30 Oct 2014 | 11:31 am
    Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (GILD)'s Sovaldi On Formulary.http://hepatitiscnewdrugs.blogspot.com.au/2...
  • Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (GILD)'s Sovaldi On Formulary

    HCV New Drug Research
    30 Oct 2014 | 7:21 am
    Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (GILD)'s Sovaldi On FormularyBy Riley McDermid, BioSpace.com Breaking News Staff The price war between dueling hepatitis C drugs added another skirmish Thursday, after pharmacy benefit manager Express Scripts Holding Co said it will likely change its standard formula to a new, cheaper unnamed AbbVie (ABBV) product instead of choosing Gilead Science (GILD)’s pricey Harvoni or Sovaldi treatments. "The cost of [Sovaldi] is unsustainable for many of our plans," Steve Miller, chief medical officer of Express…
  • Hepatitis B: future curative strategies

    MedWorm: Hepatitis B
    31 Oct 2014 | 12:53 pm
    Purpose of reviewHepatitis B virus (HBV) causes a large proportion of chronic liver disease worldwide. The limited efficiency of current treatments based on the use of nucleotide/nucleoside analogues or interferon-alpha requires the development of new therapeutic tools for the treatment of chronic HBV. We summarize the most recent therapeutic strategies designed to directly target HBV-infected hepatocytes or to restore antiviral immunity during chronic HBV infection. Recent findingsNovel therapies directly target HBV-infected hepatocytes by inducing covalently closed circular DNA degradation…
  • State won't name restaurant where worker had hepatitis A - Press Herald

    hepatitis - Google News
    31 Oct 2014 | 5:49 pm
    WCSH-TVState won't name restaurant where worker had hepatitis APress Herald“I have been trying to get the president to pay attention to the illegals in our country because there's been a spike in hepatitis C, tuberculosis and HIV, but it's going on deaf ears,” LePage said. Asked a follow-up question on hepatitis, LePage Food worker possibly exposes patrons to Hepatitis AWCSH-TVMaine CDC: Southern Maine restaurant worker may have exposed diners to Bangor Daily NewsMaine CDC: Cumberland County restaurant worker had hepatitis AWMTW PortlandWGME -NECNall 32 news…
  • Spleen

    About.com Hepatitis: What's Hot Now
    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Definition of spleen. Hepatitis.
  • add this feed to my.Alltop

    MedWorm: Hepatitis B

  • Hepatitis B: future curative strategies

    31 Oct 2014 | 12:53 pm
    Purpose of reviewHepatitis B virus (HBV) causes a large proportion of chronic liver disease worldwide. The limited efficiency of current treatments based on the use of nucleotide/nucleoside analogues or interferon-alpha requires the development of new therapeutic tools for the treatment of chronic HBV. We summarize the most recent therapeutic strategies designed to directly target HBV-infected hepatocytes or to restore antiviral immunity during chronic HBV infection. Recent findingsNovel therapies directly target HBV-infected hepatocytes by inducing covalently closed circular DNA degradation…
  • The relationship between fibrosis level and blood neutrophil to lymphocyte ratio in inactive hepatitis B carriers

    31 Oct 2014 | 12:22 pm
    ConclusionIn inactive hepatitis B carriers, the histological activity index and NLR were found to be correlated negatively. NLR can be used as a predictor of fibrosis in combination with other noninvasive markers. (Source: European Journal of Gastroenterology and Hepatology)
  • Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients

    31 Oct 2014 | 12:22 pm
    ObjectiveHepatitis B virus infection is still one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide. Liver biopsy is the gold-standard method to assess the severity of liver fibrosis, but the invasive nature of this method limits its usage. Currently, noninvasive parameters are utilized to estimate liver histology. In the present study, we aimed to investigate the relationship between the severity of fibrosis and red blood cell distribution width (RDW), platelet distribution width (PDW), mean platelet volume (MPV), and MPV and red blood cell distribution width to…
  • Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials

    30 Oct 2014 | 4:00 pm
    Abstract A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. In a breakout session, workshop attendees discussed necessary data elements and standards for the accurate measurement of DILI risk associated with new therapeutic agents in clinical trials. There was agreement that in order to achieve this goal the systematic acquisition of protocol-specified clinical measures and lab specimens from all study subjects is crucial. In addition, standard DILI terms that address the diverse clinical and pathologic signatures of…
  • Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)

    30 Oct 2014 | 4:00 pm
    Abstract The FDA guidance for industry in the premarketing clinical evaluation of drug-induced liver injury (DILI) is the most specific regulatory guidance currently available and has been useful in setting standards for the great majority of clinical indications involving subjects with a low risk of liver disorders. However, liver safety assessment faces challenges in populations with underlying liver disease, such as viral hepatitis or metastatic cancer. This is an important issue because there are currently many promising anti-viral and oncologic therapies in clinical development, with a…
 
  • add this feed to my.Alltop

    hepatitis - Google News

  • State won't name restaurant where worker had hepatitis A - Press Herald

    31 Oct 2014 | 5:49 pm
    WCSH-TVState won't name restaurant where worker had hepatitis APress Herald“I have been trying to get the president to pay attention to the illegals in our country because there's been a spike in hepatitis C, tuberculosis and HIV, but it's going on deaf ears,” LePage said. Asked a follow-up question on hepatitis, LePage Food worker possibly exposes patrons to Hepatitis AWCSH-TVMaine CDC: Southern Maine restaurant worker may have exposed diners to Bangor Daily NewsMaine CDC: Cumberland County restaurant worker had hepatitis AWMTW PortlandWGME -NECNall 32 news…
  • Viral hepatitis symposium to be held - KHON2

    31 Oct 2014 | 5:36 pm
    KHON2Viral hepatitis symposium to be heldKHON2The Dept. of Health is partnering with the Hepatitis Support Network of Hawaii, Hep Free Hawaii, and other local agencies to host “Viral Hepatitis Hawai'i – Update 2014,” a symposium for medical professionals, social service providers, and community ...Silence is Deadly: Combating the Epidemic of Viral HepatitisAIDS.gov blog (blog)HI DOH Touts New Hep C Drug As CureMaui TV News (blog)all 3 news articles »
  • Triple Therapy for Hepatitis C Infection: Bacterial Infection Risk Rises, Changes - HCPLive

    31 Oct 2014 | 3:03 pm
    HCPLiveTriple Therapy for Hepatitis C Infection: Bacterial Infection Risk Rises, ChangesHCPLiveA good adjective to describe hepatitis C virus (HCV) infection is “tricky.” Many Americans are infected and don't know it, and are chronic carriers of the virus. Patients who have HCV infection are at high risk for arthralgia, myalgias, pruritus
  • Maine: Cumberland County food service worker tests positive for hepatitis A ... - Outbreak News Today

    31 Oct 2014 | 7:01 am
    Maine: Cumberland County food service worker tests positive for hepatitis A Outbreak News TodayMaine Center for Disease Control and Prevention (Maine CDC) identified a case of acute hepatitis A virus infection in a Cumberland County food service worker, according to an advisory issued Oct. 30. The case served food while infectious from September ...
  • Maine CDC: Guess Which Restaurant Exposed You to Hepatitis A? - Food Poisoning Bulletin

    31 Oct 2014 | 6:18 am
    Food Poisoning BulletinMaine CDC: Guess Which Restaurant Exposed You to Hepatitis A?Food Poisoning BulletinDo you have clay-colored stools, dark urine, fever, jaundice, yellow eyes, abdominal cramping and weight loss? If so, you have Hepatitis A and should see a doctor. If you have these symptoms and also spent time in Cumberland County, Maine from ...
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • Spleen

    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Definition of spleen. Hepatitis.
  • The Large Intestine

    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Hepatitis. Page 6.
  • Complications of Chronic Hepatitis C

    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Chronic hepatitis C affects the liver, but it's also associated with many extrahepatic diseases. Here's a list of some of them.
  • Hepatitis C

    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Hepatitis C is a major public health problem. Hepatitis C is a disease caused by the hepatitis C virus and targets the liver, leading to inflammation. Unless the hepatitis C virus is cleared from the liver, fibrosis develops and usually leads to serious complications such as cirrhosis.
  • Is Your Skin Turning Yellow? Why It May Be...

    hepatitis.guide@about.com
    31 Oct 2014 | 4:13 am
    Jaundice is yellowing of the skin and is a classic symptom of hepatitis. Not everyone with hepatitis will develop jaundice, and sometimes people won't recognize very mild cases.
 
  • add this feed to my.Alltop

    Hepatitis Central

  • A New Hepatitis C Treatment: No Interferon or Ribavirin Required!

    The Editors at Hepatitis Central
    27 Oct 2014 | 8:09 am
    Harvoni Takes the Sting Out of Hepatitis C Treatment For the first time, hepatitis C can be cured without interferon and ribavirin, which can cause fatigue and depression. Written by David Heitz | October 26, 2014 Finally, there’s a medication to cure hepatitis C that doesn’t require use of the dreaded drugs interferon or ribavirin. The U.S. Food and Drug Administration earlier this month approved Harvoni, a once-daily tablet manufactured by Gilead Sciences. Harvoni is a combination medication that includes sofosbuvir (Sovaldi), another Gilead breakthrough treatment approved late last…
  • How Can Chronic Pain Lead to Hepatitis C?

    Nicole Cutler L.Ac.
    27 Oct 2014 | 7:54 am
    Contracted via blood-to-blood contact, Hepatitis C is an infectious virus of the liver that is easily passed on by sharing intravenous drug needles. At first consideration, Hepatitis C’s mode of transmission appears to have no relationship with chronic muscle, joint, nerve or other type of pain. However, chronic pain that leads to Hepatitis C infection is an alarming pattern that is emerging across the U.S. Chronic Pain Chronic pain is a major public health dilemma. While acute pain is a normal sensation triggered in the nervous system to alert someone of a possible injury, chronic pain is…
  • Dropout Rate for Taking Sovaldi: 400% Higher Than Observed in Clinical Trials

    The Editors at Hepatitis Central
    7 Oct 2014 | 6:47 am
    CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill By David Kroll, 9/17/14 Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus. Continue reading this entire article:…
  • The Affordability of Sovaldi

    Nicole Cutler L.Ac.
    1 Oct 2014 | 12:29 pm
    Sovaldi is currently one of the best medications approved to defeat the tenacious Hepatitis C virus. With a price tag of $1,000 per pill, this drug’s cost is probably its biggest caveat. The World Health Organization estimates that 130 million people have been infected with Hepatitis C, and many of those are far from able to afford the $84,000 needed for Sovaldi’s twelve weeks of treatment. However, the price of $1,000 per pill does not seem to apply to everyone. Besides differences in what U.S. health insurers will cover, generic licensing of Sovaldi in developing countries will…
  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
 
  • add this feed to my.Alltop

    Hepatitis C Treatment News

  • Viral hepatitis symposium to be held

    31 Oct 2014 | 5:41 pm
    … Administration (FDA) approved a new breakthrough drug to treat chronic hepatitis C … Some people with chronic hepatitis C infection develop scarring and poor liver function … Americans are infected with hepatitis C, and without proper treatment, 15 to 30 …
  • AbbVie: Strong results lessen need for big deal

    31 Oct 2014 | 3:28 pm
    … within weeks for a combination treatment for hepatitis C that may bolster earnings … years for other drugmakers to develop and win approval for their … . But others declined, including cholesterol treatments and AndroGel testosterone gel, whose …
  • AbbVie Says It’s Probably Done With Mega-Deals After Shire

    31 Oct 2014 | 2:06 pm
    … earlier. AbbVie is also developing a treatment for hepatitis C that it says … s therapy. The drugs are among new treatments that do away … , with patients taking multiple pills, some twice a day. … that minor differences in pill count or shorter duration …
  • CVS To Retain Its Growth Momentum In Q3’14 Driven By Its PBM Business

    31 Oct 2014 | 9:40 am
    … increasing its focus on developing this business. Specialty drugs treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and … specialty drug Sovaldi (a new hepatitis C drug) drove specialty revenue in …
  • UPDATE 2-AbbVie says strong results lessen need for big deal

    31 Oct 2014 | 8:50 am
    … within weeks for a combination treatment for hepatitis C that may bolster earnings … years for other drugmakers to develop and win approval for their … . But others declined, including cholesterol treatments and AndroGel testosterone gel, whose …
  • add this feed to my.Alltop

    Hepatitis News

  • Epivir and Tenofovir Appear Safe to Use During Breast-Feeding

    31 Oct 2014 | 7:56 pm
    Epivir and Viread are likely safe for women to use while breast-feeding, Reuters Health reports. Research has shown that both antiretrovirals are safe and effective against hepatitis B virus during pregnancy, but questions have remained about safety during breast-feeding.
  • AbbVie gains after Irish deal rejected

    31 Oct 2014 | 12:30 pm
    AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire, reported impressive quarterly earnings on demand for its Humira arthritis drug. "The underlying growth prospects of AbbVie don't require us to do a deal of that size," AbbVie Chief Executive Richard Gonzalez said in conference call, but added the company was keen on smaller acquisitions, particularly of treatments involving rare diseases, cancer and hepatology.
  • Is Gilead Sciences a Worthy Investment?

    30 Oct 2014 | 5:10 pm
    Gilead Sciences is having a fantastic time in 2014, with shares up 34%. The company had reported solid results for the second quarter, delivering impressive jumps in both revenue and profit and crushing estimates.
  • Hepatitis A in a Food Service Worker

    30 Oct 2014 | 12:58 pm
    Maine Center for Disease Control and Prevention identified a case of acute hepatitis A virus infection in a Cumberland County food service worker. The case served food while infectious from September 29, 2014 thru October 11, 2014.
  • EDITORIAL: The Obamacare virus

    30 Oct 2014 | 8:56 am
    Socialized health care in the United States comes by incrementalism, as if on little cat feet. Obamacare and its exchanges preserve the illusion of a free market for insurance coverage, but we're inching ever closer to the left's dream of "single-payer," a system of one-size-fits-all medical treatment organized by the government.
 
  • add this feed to my.Alltop

    Hepatitis Blog

  • Red Robin Restaurant Hepatitis A Exposure Class Action lawsuit – Missouri (2014)

    Bill Marler
    28 Oct 2014 | 5:14 pm
    Springfield Missouri Health officials administered more than 5,000 doses of the hepatitis A vaccine. On May 20, 2014, health department officials learned of a food service worker at the Red Robin restaurant who had tested positive for Hepatitis A. Individuals potentially exposed to the Hepatitis A virus dined at the restaurant between May 8 and 16. Marler Clark filed a class action lawsuit against Red Robin restaurant.  The lawsuit was filed on behalf of restaurant patrons who received hepatitis A vaccinations after alleged exposure to the hepatitis A virus at the restaurant between May 8…
  • Hepatitis A Cluster in Alabama

    Bill Marler
    27 Sep 2014 | 9:29 am
    The Alabama Department of Public Health is investigating three cases of hepatitis A in Clarke County in southwest Alabama. The department says two of the cases involve people who have a history of international travel. The health department says signs of hepatitis A appear 15 to 50 days after exposure and commonly include mild fever, loss of appetite, nausea, vomiting and tiredness. The disease varies in severity from about two weeks to six weeks or more. The department says casual contact, such as at an office or school, does not transmit the virus. The risk increases when people are in…
  • 165 Sick with Hepatitis A Linked to Townsend Farms Organic Antioxidant Blend

    Bill Marler
    25 Sep 2014 | 9:52 pm
    165 people were confirmed to have become ill from hepatitis A after eating ‘Townsend Farms Organic Antioxidant Blend’ in 10 states: Arizona (24), California (80), Colorado (29), Hawaii (8), New Hampshire (1), New Jersey (1), New Mexico (11), Nevada (6), Utah (3), and Wisconsin (2). [Note: The cases reported from Wisconsin resulted from exposure to the product in California, the cases reported from New Hampshire reported fruit exposure during travel to Nevada, and the case reported in New Jersey was a household contact of a confirmed case from Colorado.] Eight of the confirmed cases were…
  • Whataburger Linked to Hepatitis A Scare

    Bill Marler
    21 Aug 2014 | 9:12 pm
    Austin Texas health officials are alerting the public about possible hepatitis A exposure at a Whataburger in Central Austin. A restaurant employee there at the 2800 Guadalupe St. location has been diagnosed with the hepatitis A virus. Hepatitis A is a contagious liver disease that is usually spread when a person ingests something that has been contaminated with the feces of an infected person, including contaminated food or water. Signs and symptoms of hepatitis A can include the following Fever Fatigue Loss of appetite Nausea Vomiting Abdominal discomfort Dark urine Clay-colored bowel…
  • Another Reason for Hepatitis A Vaccines – Your Restaurant Remains Closed

    Bill Marler
    19 Jul 2014 | 5:09 am
    Tortilla Marissa’s, a Mexican restaurant in Fort Collins, CO, will not reopen until August 9 because of the Hepatitis A scare that the restaurant faced at the end of June, according to the Coloradoan. The Larimer County Health Department has advised the owners to keep the restaurant closed that long due to the virus’ relatively long incubation period, which averages 28 days but can last up to 50 days in some cases. The restaurant originally closed on June 27, a day after an employee tested positive for the virus, which has a high risk of being spread when an infected person handles…
 
  • add this feed to my.Alltop

    HCV New Drug Research

  • At The Crossroads: The Rise Of Hepatitis C And The Fight To Stop It

    31 Oct 2014 | 4:33 am
    A new series from Rhode Island Public RadioAt The Crossroads: The Rise Of Hepatitis C And The Fight To Stop ItProgram Update Oct 29New Hepatitis C Drugs May Push State Over BudgetBy Kristin GourlayProviding medical assistance to low income Rhode Islanders will cost the state more than projected. One of the major factors behind the increase is the cost of two new drugs.                   Read moreOpioid Addiction Crisis Fuels Another: Hep CBy Kristin Gourlay Addiction usually leaves a wake of chaos, and all kinds of casualties - marriages,…
  • Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (GILD)'s Sovaldi On Formulary

    30 Oct 2014 | 7:21 am
    Express Scripts Says AbbVie (ABBV)'s Drug Could Displace Gilead Sciences, Inc. (GILD)'s Sovaldi On FormularyBy Riley McDermid, BioSpace.com Breaking News Staff The price war between dueling hepatitis C drugs added another skirmish Thursday, after pharmacy benefit manager Express Scripts Holding Co said it will likely change its standard formula to a new, cheaper unnamed AbbVie (ABBV) product instead of choosing Gilead Science (GILD)’s pricey Harvoni or Sovaldi treatments. "The cost of [Sovaldi] is unsustainable for many of our plans," Steve Miller, chief medical officer of Express…
  • 117,000 hepatitis C patients receive Sovaldi so far

    29 Oct 2014 | 5:01 am
    117,000 hepatitis C patients receive Sovaldi so farBreakthrough drug has made $8.5bn for Gilead this yearGilead Sciences' blockbuster hepatitis C drug Sovaldi has been used in around 117,000 people since its launch at the end of last year, said the company in its latest financial report.Sovaldi (sofosbuvir), which allows patients to be treated without the need for weekly injectable interferon, has been the most lucrative pharma launch of all time, and has recorded revenues of $8.5bn in the first nine months of 2014 and $2.8bn for the three-month period between July and September.This uptake…
  • Insurers May Cover Costly Hepatitis C Drugs Only For The Very Ill

    28 Oct 2014 | 10:12 am
    Insurers May Cover Costly Hepatitis C Drugs Only For The Very IllTuesday, October 28, 2014 Michelle Andrews / NPRIn the past year, hepatitis C drugs that promise higher cure rates and fewer side effects have given fresh hope to millions who are living with the chronic liver disease.But many patients whose livers haven't been significantly scarred by the virus face a vexing reality: They're not sick enough to qualify for the drugs that could prevent them from getting sicker.An estimated 3.2 million people are infected with hepatitis C virus. Many public and private insurers are restricting…
  • UPDATE 3-Aetna sees higher medical cost spending than expected

    28 Oct 2014 | 10:08 am
    UPDATE 3-Aetna sees higher medical cost spending than expected(Recasts to focus on medical costs)By Caroline HumerOct 28 (Reuters) - Aetna Inc, the third-largest U.S. health insurer, said on Tuesday it expects 2014 medical costs to increase at the high end of its forecasts, underpinning investor concerns that years of stabilized medical use could be ending.Shares in Aetna fell 2.2 percent and others insurers including UnitedHealth Group Inc and WellPoint Inc also fell.Aetna said that in the third quarter, it experienced an unexpected rise in its medical cost ratio due to more spending on…
Log in